Advertisement

Comparison of Three-Year Outcomes After Primary Percutaneous Coronary Intervention in Patients With Left Ventricular Ejection Fraction <40% Versus ≥40% (from the HORIZONS-AMI Trial)

Published:October 04, 2012DOI:https://doi.org/10.1016/j.amjcard.2012.08.040
      Left ventricular (LV) dysfunction and multivessel disease (MVD) have been associated with greater mortality after ST-segment elevation myocardial infarction. The aim of this study was to evaluate the impact of LV dysfunction and MVD in patients with ST-segment elevation myocardial infarctions treated with primary percutaneous coronary intervention (PCI). Patients from the Harmonizing Outcomes With Revascularization and Stents in Acute Myocardial Infarction (HORIZONS-AMI) trial treated with primary PCI in whom baseline LV function was assessed using left ventriculography were included in this study. Early and late (3-year) outcomes were examined in groups of patients with reduced (<40%) and preserved (≥40%) LV ejection fractions (LVEFs), further stratified by the presence of MVD. A total of 2,430 patients were included. Patients with reduced LVEFs were older; were more likely to be women; were more likely to have histories of myocardial infarction, PCI, and heart failure; and were more likely to present in heart failure. Patients with reduced LVEFs had greater 30-day (8.9% vs 0.9%, hazard ratio 9.81, 95% confidence interval 5.23 to 18.42, p <0.0001) and 3-year (17.1% vs 3.7%, hazard ratio 5.03, 95% confidence interval 3.37 to 7.50, p <0.0001) mortality. Among patients with LVEFs <30% (n = 45), 30% to 40% (n = 157), 40% to 50% (n = 373), 50% to 60% (n = 659), and ≥60% (n = 1,196), 3-year mortality was 29.4%, 13.5%, 6.4%, 3.8%, and 2.9%, respectively (p for trend <0.0001). MVD was associated with greater mortality in patients with preserved but not reduced LVEFs. By multivariate analysis, LV dysfunction was the strongest predictor of 30-day and 3-year mortality. In conclusion, the presence of LV dysfunction as assessed on baseline left ventriculography in patients who undergo primary PCI in the contemporary era is a powerful predictor of early and late mortality, regardless of the extent of coronary artery disease.
      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to American Journal of Cardiology
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • De Luca G.
        Prognostic assessment of patients with acute myocardial infarction treated with primary angioplasty: implications for early discharge.
        Circulation. 2004; 109: 2737-2743
        • Halkin A.
        • Singh M.
        • Nikolsky E.
        • Grines C.L.
        • Tcheng J.E.
        • Garcia E.
        • Cox D.A.
        • Turco M.
        • Stuckey T.D.
        • Na Y.
        • Lansky A.J.
        • Gersh B.J.
        • O'Neill W.W.
        • Mehran R.
        • Stone G.W.
        Prediction of mortality after primary percutaneous coronary intervention for acute myocardial infarction: the CADILLAC risk score.
        J Am Coll Cardiol. 2005; 45: 1397-1405
        • Marenzi G.
        • Moltrasio M.
        • Assanelli E.
        • Lauri G.
        • Marana I.
        • Grazi M.
        • Rubino M.
        • De Metrio M.
        • Veglia F.
        • Bartorelli A.L.
        Impact of cardiac and renal dysfunction on inhospital morbidity and mortality of patients with acute myocardial infarction undergoing primary angioplasty.
        Am Heart J. 2007; 153: 755-762
        • DeGeare V.S.
        • Boura J.A.
        • Grines L.L.
        • O'neill W.W.
        • Grines C.L.
        Predictive value of the Killip classification in patients undergoing primary percutaneous coronary intervention for acute myocardial infarction.
        Am J Cardiol. 2001; 87: 1035-1038
        • Dziewierz A.
        • Siudak Z.
        • Rakowski T.
        • Zasada W.
        • Dubiel J.S.
        • Dudek D.
        Impact of multivessel coronary artery disease and noninfarct-related artery revascularization on outcome of patients with ST-elevation myocardial infarction transferred for primary percutaneous coronary intervention (from the EUROTRANSFER registry).
        Am J Cardiol. 2010; 106: 342-347
        • Mehta R.H.
        • O'neill W.W.
        • Harjai K.J.
        • Cox D.A.
        • Brodie B.R.
        • Boura J.
        • Grines L.
        • Stone G.W.
        • Grines C.L.
        Primary Angioplasty in Myocardial Infarction (PAMI) and the Controlled Abciximab and Device Investigation to Lower Late Angioplasty Complications (CADILLAC) Investigators. Prediction of one-year mortality among 30-day survivors after primary percutaneous coronary interventions.
        Am J Cardiol. 2006; 97: 817-822
        • Stone G.W.
        • Lansky A.J.
        • Pocock S.J.
        • Gersh B.J.
        • Dangas G.
        • Wong S.C.
        • Witzenbichler B.
        • Guagliumi G.
        • Peruga J.Z.
        • Brodie B.R.
        • Dudek D.
        • Möckel M.
        • Ochala A.
        • Kellock A.
        • Parise H.
        • Mehran R.
        • Investigators H-AT
        Paclitaxel-eluting stents versus bare-metal stents in acute myocardial infarction.
        N Engl J Med. 2009; 360: 1946-1959
        • Stone G.W.
        • Witzenbichler B.
        • Guagliumi G.
        • Peruga J.Z.
        • Brodie B.R.
        • Dudek D.
        • Kornowski R.
        • Hartmann F.
        • Gersh B.J.
        • Pocock S.J.
        • Dangas G.
        • Wong S.C.
        • Kirtane A.J.
        • Parise H.
        • Mehran R.
        • Investigators H-AT
        Bivalirudin during primary PCI in acute myocardial infarction.
        N Engl J Med. 2008; 358: 2218-2230
        • Granger C.B.
        • McMurray J.J.
        • Yusuf S.
        • Held P.
        • Michelson E.L.
        • Olofsson B.
        • Ostergren J.
        • Pfeffer M.A.
        • Swedberg K.
        Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function intolerant to angiotensin-converting-enzyme inhibitors: the CHARM-Alternative trial.
        Lancet. 2003; 362: 772-776
        • Pfeffer M.A.
        • Braunwald E.
        • Moye L.A.
        • Basta L.
        • Brown E.J.
        • Cuddy T.E.
        • Davis B.R.
        • Geltman E.M.
        • Goldman S.
        • Flaker G.C.
        • Klein M.
        • Lamas G.A.
        • Packer M.
        • Rouleau J.
        • Rouleau J.L.
        • Rutherford J.
        • Wertheimer J.H.
        • Hawkins C.M.
        The SAVE Investigators. Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. Results of the survival and ventricular enlargement trial.
        N Engl J Med. 1992; 327: 669-677
        • Pitt B.
        • Remme W.
        • Zannad F.
        • Neaton J.
        • Martinez F.
        • Roniker B.
        • Bittman R.
        • Hurley S.
        • Kleiman J.
        • Gatlin M.
        Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction.
        N Engl J Med. 2003; 348: 1309-1321
        • Kober L.
        • Torp-Pedersen C.
        • Carlsen J.E.
        • Bagger H.
        • Eliasen P.
        • Lyngborg K.
        • Videbaek J.
        • Cole D.S.
        • Auclert L.
        • Pauly N.C.
        Trandolapril Cardiac Evaluation (TRACE) Study Group. A clinical trial of the angiotensin-converting-enzyme inhibitor trandolapril in patients with left ventricular dysfunction after myocardial infarction.
        N Engl J Med. 1995; 333: 1670-1676
        • Bardy G.H.
        • Lee K.L.
        • Mark D.B.
        • Poole J.E.
        • Packer D.L.
        • Boineau R.
        • Domanski M.
        • Troutman C.
        • Anderson J.
        • Johnson G.
        • McNulty S.E.
        • Clapp-Channing N.
        • Davidson-Ray L.D.
        • Fraulo E.S.
        • Fishbein D.P.
        • Luceri R.M.
        • Ip J.H.
        Amiodarone or an implantable cardioverter-defibrillator for congestive heart failure.
        N Engl J Med. 2005; 352: 225-237
        • Moss A.J.
        • Zareba W.
        • Hall W.J.
        • Klein H.
        • Wilber D.J.
        • Cannom D.S.
        • Daubert J.P.
        • Higgins S.L.
        • Brown M.W.
        • Andrews M.L.
        Prophylactic implantation of a defibrillator in patients with myocardial infarction and reduced ejection fraction.
        N Engl J Med. 2002; 346: 877-883
        • Hohnloser S.H.
        • Kuck K.H.
        • Dorian P.
        • Roberts R.S.
        • Hampton J.R.
        • Hatala R.
        • Fain E.
        • Gent M.
        • Connolly S.J.
        Prophylactic use of an implantable cardioverter-defibrillator after acute myocardial infarction.
        N Engl J Med. 2004; 351: 2481-2488
        • Steinbeck G.
        • Andresen D.
        • Seidl K.
        • Brachmann J.
        • Hoffmann E.
        • Wojciechowski D.
        • Kornacewicz-Jach Z.
        • Sredniawa B.
        • Lupkovics G.
        • Hofgartner F.
        • Lubinski A.
        • Rosenqvist M.
        • Habets A.
        • Wegscheider K.
        • Senges J.
        Defibrillator implantation early after myocardial infarction.
        N Engl J Med. 2009; 361: 1427-1436
        • Daneault B.
        • Do D.H.
        • Maltais A.
        • Berube S.
        • Harvey R.
        • Gervais A.
        • Dalery K.
        • Nguyen M.
        Reduction of delays in primary percutaneous coronary intervention.
        Can J Cardiol. 2011; 27: 562-566
        • Sederholm Lawesson S.
        • Todt T.
        • Alfredsson J.
        • Janzon M.
        • Stenestrand U.
        • Swahn E.
        Gender difference in prevalence and prognostic impact of renal insufficiency in patients with ST-elevation myocardial infarction treated with primary percutaneous coronary intervention.
        Heart. 2011; 97: 308-314
        • Cavender M.A.
        • Milford-Beland S.
        • Roe M.T.
        • Peterson E.D.
        • Weintraub W.S.
        • Rao S.V.
        Prevalence, predictors, and in-hospital outcomes of non-infarct artery intervention during primary percutaneous coronary intervention for ST-segment elevation myocardial infarction (from the National Cardiovascular Data Registry).
        Am J Cardiol. 2009; 104: 507-513
        • Sorajja P.
        • Gersh B.J.
        • Cox D.A.
        • McLaughlin M.G.
        • Zimetbaum P.
        • Costantini C.
        • Stuckey T.
        • Tcheng J.E.
        • Mehran R.
        • Lansky A.J.
        • Grines C.L.
        • Stone G.W.
        Impact of multivessel disease on reperfusion success and clinical outcomes in patients undergoing primary percutaneous coronary intervention for acute myocardial infarction.
        Eur Heart J. 2007; 28: 1709-1716
        • Claessen B.E.
        • van der Schaaf R.J.
        • Verouden N.J.
        • Stegenga N.K.
        • Engstrom A.E.
        • Sjauw K.D.
        • Kikkert W.J.
        • Vis M.M.
        • Baan J.
        • Koch K.T.
        • de Winter R.J.
        • Tijssen J.G.
        • Piek J.J.
        • Henriques J.P.
        Evaluation of the effect of a concurrent chronic total occlusion on long-term mortality and left ventricular function in patients after primary percutaneous coronary intervention.
        J Am Coll Cardiol Intv. 2009; 2: 1128-1134
        • van der Schaaf R.J.
        • Vis M.M.
        • Sjauw K.D.
        • Koch K.T.
        • Baan J.
        • Tijssen J.G.P.
        • de Winter R.J.
        • Piek J.J.
        • Henriques J.P.S.
        Impact of multivessel coronary disease on long-term mortality in patients with ST-elevation myocardial infarction is due to the presence of a chronic total occlusion.
        Am J Cardiol. 2006; 98: 1165-1169
        • Mehran R.
        • Pocock S.
        • Nikolsky E.
        • Dangas G.D.
        • Clayton T.
        • Claessen B.E.
        • Caixeta A.
        • Feit F.
        • Manoukian S.V.
        • White H.
        • Bertrand M.
        • Ohman E.M.
        • Parise H.
        • Lansky A.J.
        • Lincoff A.M.
        • Stone G.W.
        Impact of bleeding on mortality after percutaneous coronary intervention results from a patient-level pooled analysis of the REPLACE-2 (Randomized Evaluation of PCI Linking Angiomax to Reduced Clinical Events), ACUITY (Acute Catheterization and Urgent Intervention Triage Strategy), and HORIZONS-AMI (Harmonizing Outcomes With Revascularization and Stents in Acute Myocardial Infarction) trials.
        J Am Coll Cardiol Intv. 2011; 4: 654-664
        • Antman E.M.
        • Anbe D.T.
        • Armstrong P.W.
        • Bates E.R.
        • Green L.A.
        • Hand M.
        • Hochman J.S.
        • Krumholz H.M.
        • Kushner F.G.
        • Lamas G.A.
        • Mullany C.J.
        • Ornato J.P.
        • Pearle D.L.
        • Sloan M.A.
        • Smith Jr, S.C.
        ACC/AHA guidelines for the management of patients with ST-elevation myocardial infarction–executive summary. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 1999 Guidelines for the Management of Patients With Acute Myocardial Infarction).
        J Am Coll Cardiol. 2004; 44: 671-719
        • Homma S.
        • Thompson J.L.
        • Pullicino P.M.
        • Levin B.
        • Freudenberger R.S.
        • Teerlink J.R.
        • Ammon S.E.
        • Graham S.
        • Sacco R.L.
        • Mann D.L.
        • Mohr J.P.
        • Massie B.M.
        • Labovitz A.J.
        • Anker S.D.
        • Lok D.J.
        • Ponikowski P.
        • Estol C.J.
        • Lip G.Y.
        • Di Tullio M.R.
        • Sanford A.R.
        • Mejia V.
        • Gabriel A.P.
        • Del Valle M.L.
        • Buchsbaum R.
        Warfarin and aspirin in patients with heart failure and sinus rhythm.
        N Engl J Med. 2012; 366: 1859-1869
        • Mega J.L.
        • Braunwald E.
        • Wiviott S.D.
        • Bassand J.P.
        • Bhatt D.L.
        • Bode C.
        • Burton P.
        • Cohen M.
        • Cook-Bruns N.
        • Fox K.A.
        • Goto S.
        • Murphy S.A.
        • Plotnikov A.N.
        • Schneider D.
        • Sun X.
        • Verheugt F.W.
        • Gibson C.M.
        Rivaroxaban in patients with a recent acute coronary syndrome.
        N Engl J Med. 2012; 366: 9-19
        • Wallentin L.
        • Becker R.C.
        • Budaj A.
        • Cannon C.P.
        • Emanuelsson H.
        • Held C.
        • Horrow J.
        • Husted S.
        • James S.
        • Katus H.
        • Mahaffey K.W.
        • Scirica B.M.
        • Skene A.
        • Steg P.G.
        • Storey R.F.
        • Harrington R.A.
        • Freij A.
        • Thorsen M.
        Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
        N Engl J Med. 2009; 361: 1045-1057
        • Feldman A.M.
        • Klein H.
        • Tchou P.
        • Murali S.
        • Hall W.J.
        • Mancini D.
        • Boehmer J.
        • Harvey M.
        • Heilman M.S.
        • Szymkiewicz S.J.
        • Moss A.J.
        Use of a wearable defibrillator in terminating tachyarrhythmias in patients at high risk for sudden death: results of the WEARIT/BIROAD.
        Pacing Clin Electrophysiol. 2004; 27: 4-9
        • Politi L.
        • Sgura F.
        • Rossi R.
        • Monopoli D.
        • Guerri E.
        • Leuzzi C.
        • Bursi F.
        • Sangiorgi G.M.
        • Modena M.G.
        A randomised trial of target-vessel versus multi-vessel revascularisation in ST-elevation myocardial infarction: major adverse cardiac events during long-term follow-up.
        Heart. 2010; 96: 662-667
        • Kornowski R.
        • Mehran R.
        • Dangas G.
        • Nikolsky E.
        • Assali A.
        • Claessen B.E.
        • Gersh B.J.
        • Wong S.C.
        • Witzenbichler B.
        • Guagliumi G.
        • Dudek D.
        • Fahy M.
        • Lansky A.J.
        • Stone G.W.
        Prognostic impact of staged versus “one-time” multivessel percutaneous intervention in acute myocardial infarction: analysis from the HORIZONS-AMI (Harmonizing Outcomes With Revascularization and Stents in Acute Myocardial Infarction) trial.
        J Am Coll Cardiol. 2011; 58: 704-711
        • Hannan E.L.
        • Samadashvili Z.
        • Walford G.
        • Holmes Jr, D.R.
        • Jacobs A.K.
        • Stamato N.J.
        • Venditti F.J.
        • Sharma S.
        • King III, S.B.
        Culprit vessel percutaneous coronary intervention versus multivessel and staged percutaneous coronary intervention for ST-segment elevation myocardial infarction patients with multivessel disease.
        J Am Coll Cardiol Intv. 2010; 3: 22-31